Imagine you could give your patients a faster and more accurate diagnosis of their cardiac condition. Envisage that you could identify coronary artery disease with better accuracy thanks to advanced PET imaging. And what if you could make the entire diagnostic process more patient-friendly with the latest 13N-NH3-based PET imaging? Think of all the advantages: rapid throughput, lower radiation burden, and a wealth of clinical information.
With our vast experience in developing versatile cyclotrons integrated in total solutions, IBA makes this a reality and launches Akuracy®.
Discover it at EACVI 2023, May 10-12, in Barcelona during live presentations at IBA booth A402.
Discover why our total solution is the (cardio)logical choice for you.
ABOUT IBA
INTEGRATED MEDICAL SOLUTION AGAINST CANCER
Founded in 1986, IBA is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer.
Based on 35 years of experience, IBA RadioPharma Solutions helps nuclear medicine department to design, build and operate PET center for the production of radiopharmaceuticals used for the detection and treatment of cancer and other critical diseases.
IBA is the world leader for the supply of PET & SPECT cyclotrons for radiopharmaceuticals production. Headquartered in Belgium, IBA installed and supports over 350 cyclotrons across the world.
